Inhibrx Biosciences, Inc.
INBRX-106
head and neck squamous cell carcinoma
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on INBRX-106 for head and neck squamous cell carcinoma is in focus around Date TBD.
Primary source
· SEC 8-K
verified 12h ago
“We plan to announce PFS data from the randomized Phase 2/3 trial in HNSCC in combination with pembrolizumab in the fourth quarter of 2026 at the European Society for Medical Oncology (“ESMO”) 2026 Congress.”